Regado Biosciences, Inc. to Provide Third Quarter 2013 Financial Results
Conference Call and Webcast Scheduled for November 7, 2013, 8:30 a.m. ET
BASKING RIDGE, N.J., Oct. 31, 2013 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced Regado's senior management will host a third quarter earnings conference call and live audio webcast on Thursday, November 7, 2013, at 8:30 a.m. ET to discuss recent activities and upcoming plans.
Interested participants and investors may access the conference call by dialing (877) 870-4263 (U.S.), (855) 669-9657 (Canada) or (412) 317-0790 (international). An audio webcast will be accessible via the Investor Relations section of the Regado website, www.regadobio.com.
A telephonic replay of the call will be available for 90 days beginning approximately one hour following the end of the conference call. Access numbers for this replay are (877) 344-7529 (U.S./Canada) and (412) 317-0088 (international); conference ID: 10036564. The webcast replay will remain available for 90 days in the Investor Relations section of the Regado website.
ABOUT REGADO BIOSCIENCES
Regado Biosciences, Inc. is a biopharmaceutical company focused on the development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications. Regado is pioneering the development of two-component drug systems consisting of a therapeutic aptamer and its specific active control agent. The company's lead product candidate, REG1, is a two-component system consisting of pegnivacogin, an anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary oligonucleotide active control agent, anivamersen. REG1 is being developed for use in patients with a wide variety of acute coronary syndromes, or ACS, undergoing a percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. Regado's actively controllable product candidates have the potential to improve patient outcomes, enhance the patient experience and reduce overall treatment costs. More information can be found at www.regadobio.com.
For more information on Regado's Phase 3 REGULATE-PCI clinical study, please visit:
Investors - Joshua Drumm, Ph.D.
firstname.lastname@example.org; (212) 375-2664
Media - Andrew Mielach
email@example.com; (212) 375-2694
SOURCE Regado Biosciences, Inc.
More by this Source
Regado Biosciences Strengthens Executive Leadership
Dec 09, 2013, 07:30 ET
Regado Biosciences, Inc. to Present at Oppenheimer's 24th Annual Healthcare Conference
Dec 06, 2013, 16:30 ET
Regado Biosciences, Inc. Adds Global Pharmaceutical Business Veteran to Board of Directors
Nov 18, 2013, 16:50 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.